← Leaderboards
Bryce B Reeve
Univ Of North Carolina Chapel Hill
$11,567,326
Attributed
$18,322,587
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,083,507 · 8
FDA$7,175,880 · 5
By mechanism
U19$6,027,564 · 4
R01$4,781,932 · 2
UH3$4,513,361 · 2
UG3$2,162,519 · 2
R25$2,147,741 · 1
U01$1,626,270 · 2
Top collaborators
- Pamela S Hinds9 shared
- Ethan M. Basch5 shared
- Ronald Chen5 shared
- Laura E Schanberg4 shared
- Kanecia Obie Zimmerman3 shared
- Bryan J. Weiner2 shared
- Stephanie Brooke Wheeler2 shared
- Justin N Baker1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Joseph G Ibrahim$17,599,307
- Jen Jen Yeh$14,819,320
- Bryan J. Weiner$11,631,061
- Peggy Leatt$603,041
- Michael P Pignone$5,209,599
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMultidisciplinaryReportingSitePatient Outcomes AssessmentsCancer TherapyDiagnosisCancer PatientFatigueSymptomsQuestionnairesPsychometricsCaringInterviewPropertyData ReportingLearningScienceChildDesignQuality Of CareChildhoodProceduresTranslating
Grant awards (34)
Expanding the Observer-Reported Communication Ability (ORCA) Measure: Measuring the communication ability of individuals with rare, neurodevelopmental disorders$1,049,722
UH3 · FY2025 · FD · contact PI
Expanding the Observer-Reported Communication Ability (ORCA) Measure: Measuring the communication ability of individuals with rare, neurodevelopmental disorders$763,854
UH3 · FY2024 · FD · contact PI
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)$1,510,088
UH3 · FY2023 · FD
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)$1,189,697
UH3 · FY2023 · FD
Expanding the Observer-Reported Communication Ability (ORCA) Measure: Measuring the communication ability of individuals with rare, neurodevelopmental disorders$763,398
UG3 · FY2023 · FD · contact PI
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Public-Private Partnership$500,000
U01 · FY2021 · FD
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)$1,399,121
UG3 · FY2019 · FD
CHANGE OF GRANTEE INSTITUTION: Creating and Validating Child Adverse Event Reporting in Oncology Trials$626,421
R01 · FY2018 · CA · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$616,962
R01 · FY2017 · CA · contact PI
Cancer Care Quality Research Training Program$401,402
R25 · FY2017 · CA
Creating and Validating Child Adverse Event Reporting in Oncology Trials$14,711
R01 · FY2017 · CA · contact PI
Cancer Care Quality Research Training Program$405,045
R25 · FY2016 · CA
PROMIS Validation in Prospective Population-based Prostate Cancer Research Study$150,000
R01 · FY2016 · CA
Creating and Validating Child Adverse Event Reporting in Oncology Trials$64,857
R01 · FY2016 · CA · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$1
R01 · FY2016 · CA · contact PI
Enhancing Clinical Meaningfulness And Usefulness Of PROMIS Pediatric Measures Via Validation In Children And Adolescents With Rheumatic Disease, Cancer, Or Inflammatory Bowel Disease$1,952,812
U19 · FY2015 · AR · contact PI
Clinical Validation of PROMIS Pediatric Measures in Diverse Research Networks$1,598,695
U19 · FY2015 · AR · contact PI
Clinical Validation of PROMIS Pediatric Measures in Diverse Research Networks$1,125,508
U19 · FY2015 · AR · contact PI
Enhancing Clinical Meaningfulness And Usefulness Of PROMIS Pediatric Measures Via Validation In Children And Adolescents With Rheumatic Disease, Cancer, Or Inflammatory Bowel Disease$983,988
U19 · FY2015 · AR · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$625,352
R01 · FY2015 · CA · contact PI
Cancer Care Quality Research Training Program$429,798
R25 · FY2015 · CA
Enhancing Meaningfulness and Usefulness of Pediatric and Caregiver PROMIS Measures Across Illness Groups$366,561
U19 · FY2015 · AR · contact PI
PROMIS Validation in Prospective Population-based Prostate Cancer Research Study$280,122
R01 · FY2015 · CA
Creating and Validating Child Adverse Event Reporting in Oncology Trials$64,857
R01 · FY2015 · CA · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$623,121
R01 · FY2014 · CA · contact PI
Cancer Care Quality Research Training Program$454,498
R25 · FY2014 · CA
PROMIS Validation in Prospective Population-based Prostate Cancer Research Study$421,719
R01 · FY2014 · CA · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$48,511
R01 · FY2014 · CA · contact PI
Creating and Validating Child Adverse Event Reporting in Oncology Trials$698,123
R01 · FY2013 · CA · contact PI
Cancer Care Quality Research Training Program$456,998
R25 · FY2013 · CA
PROMIS Validation in Prospective Population-based Prostate Cancer Research Study$263,315
R01 · FY2013 · CA · contact PI
PROMIS Pediatrics: Longitudinal Validation and Linking Pediatric and Adult Item B$200,000
U01 · FY2013 · AR · contact PI
PROMIS Pediatrics: Longitudinal Validation and Linking Pediatric and Adult Item B$926,270
U01 · FY2012 · AR · contact PI
PROMIS Validation in Prospective Population-based Prostate Cancer Research Study$283,860
R01 · FY2012 · CA · contact PI